<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428451</url>
  </required_header>
  <id_info>
    <org_study_id>N02112</org_study_id>
    <nct_id>NCT03428451</nct_id>
  </id_info>
  <brief_title>Treatment Versus Prophylaxis Against TURP Syndrome: Role Of Hypertonic Saline</brief_title>
  <official_title>The Efficacy and Safety of Preoperative Intravenous Infusion of Hypertonic Saline (3%) During TURP in Prevention Versus Its Need for Correction of Hyponatraemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Mohamed ELbadawy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the efficacy and safety of intravenous infusion of
      hypertonic saline in BPH patients, candidates for TURP surgery using the monopolar electric
      resectoscope in prevention of hyponatraemia and TUR syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TURP remains the surgical gold standard for the treatment of benign prostatic hyperplasia
      (BPH), which is the most common surgical procedure performed on male patients over 60 years
      of age. During TURP the wide plexus of venous sinuses is often opened. Non-conductive
      irrigation fluid is required during the use of monopolar electric resectoscope to clear the
      operating field. This hypotonic, electrolyte-free, nonconductive distension solution contains
      no electrolytes, and excessive absorption of it can cause fluid overload and dilutional
      hyponatremia. This study will be conducted on 60 patients ASA class I - III BPH patients,
      candidates for TURP surgery using the monopolar electric resectoscope. patients will be
      allocated into one of three study groups(n=20 in each). Group A patients will receive NaCl 3%
      (hypertonic saline) at a dose of 4 ml/kg/hr; Group B patients will receive NaCl 3%
      (hypertonic saline) at a dose of 2 ml/kg/hr; while group C patients will receive NaCl 0.9%
      (normal saline) at a dose of 6 ml/kg/hr. All intra-venous infusions will be started 30
      minutes before the subarachnoid block, and continued all through the procedure at the same
      rate. Hemodynamic parameters, s. sodium and osmolality, incidence of TUR syndrome, the need
      of hypertonic saline for treatment of hyponatraemia and need for ICU admission will be
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum sodium in mEq/L ( Normal s.sodium 135-145 mEq/L)</measure>
    <time_frame>72 hours</time_frame>
    <description>Hyponatremia was defined as a serum sodium &lt; 130 mEq/L</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transurethral Resection of Prostate Syndrome</condition>
  <arm_group>
    <arm_group_label>NaCl 3% hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive NaCl 3% hypertonic saline at a dose of 4 ml/kg/hr (Group A) and 2ml/kg/hr (Group B) ; 30 min before the subarachnoid block, and continued all through the procedure at the same rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9% normal saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive NaCl 0.9% normal saline at a dose of 6ml/kg/hr (Group c); 30 min before the subarachnoid block, and continued all through the procedure at the same rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 3% hypertonic saline</intervention_name>
    <description>NaCl 3% hypertonic saline is a crystalloid solution with osmolarity higher than that of plasma.</description>
    <arm_group_label>NaCl 3% hypertonic saline</arm_group_label>
    <other_name>hypertonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% normal saline</intervention_name>
    <description>NaCl 0.9% normal saline is a crystalloid isotonic solution</description>
    <arm_group_label>NaCl 0.9% normal saline</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class I - III BPH patients

        Exclusion Criteria:

          -  Refusal of the patient

          -  Patients having any condition contra-indicating regional anesthesia e.g impaired
             coagulation.

          -  Electrolyte imbalance,

          -  Uncontrolled hypertension,

          -  Congestive heart failure or being allergic to local anesthetics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult male BPH patients</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed ELbadawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine- Cairo University- Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed ELbadawy, MD</last_name>
    <phone>01064249076</phone>
    <phone_ext>11562</phone_ext>
    <email>elbadawyahmed89@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nazmy Seif, MD</last_name>
    <phone>01227400808</phone>
    <phone_ext>11562</phone_ext>
    <email>drnazmyseif@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed elbadawy</last_name>
      <phone>01064249076</phone>
      <email>elbadawyahmed89@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed ELbadawy</investigator_full_name>
    <investigator_title>Ahmed Mohamed ELbadawy- Clinical investigator , Cairo University</investigator_title>
  </responsible_party>
  <keyword>TURP</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>TURP syndrome</keyword>
  <keyword>hyponatraemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access.Seeking consent for sharing IPD from trial participants with adequate assurance that patient privacy and confidentiality can be maintained;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

